Literature DB >> 7673549

Serum levels of soluble CD23 in patients with bullous pemphigoid.

N Maekawa1, H Hosokawa, H Soh, M Kasahara, H Izumi, J Yodoi, Y Asada.   

Abstract

In this study, we tested the serum levels of soluble CD23 (sCD23) in 27 bullous pemphigoid (BP) patients and compared them with the disease activity. Soluble CD23 is the cleaved portion of the low affinity Fc receptor for IgE (Fc epsilon RII/CD23) which has an affinity for IgE and regulates IgE synthesis. Although bullous pemphigoid (BP) is a subepidermal blistering disease characterized by IgG class autoantibodies against the basement membrane of stratified squamous epithelia, several IgE-related phenomena have been reported. Recently, we have shown that Fc epsilon RII-expressing and IgE-bearing cells are detectable in the lesional skin and concluded that an IgE-Fc epsilon RII/CD23 system may be involved in the pathogenesis of this disease. The serum level of sCD23 in BP patients was significantly higher than healthy controls (p < 0.01). In 11 out of 12 patients, the alteration of serum sCD23 levels correlated well with the disease activity. Thus the serum level of sCD23 is useful as a new parameter for assessing the level of disease activity in BP. High levels of sCD23 may represent part of an IgE-mediated immune reaction which may play a role in the pathogenesis of BP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673549     DOI: 10.1111/j.1346-8138.1995.tb03394.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  6 in total

1.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

2.  Characterization of a constitutive type III nitric oxide synthase in human U937 monocytic cells: stimulation by soluble CD23.

Authors:  V Roman; N Dugas; A Abadie; C Amirand; H Zhao; B Dugas; J P Kolb
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

Review 3.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

4.  Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.

Authors:  Arata Hibi; Yuto Kasahara; Yoshitaka Ishihara; Koichi Hata; Norihisa Hosokawa; Takahiko Nakagawa
Journal:  CEN Case Rep       Date:  2020-01-28

Review 5.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

Review 6.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.